



INTERIM RESULTS 2023

28 August 2023



Disclaimer

This presentation has been prepared by HBM Holdings Limited (the “Company”) solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

This document has been prepared by the Company solely for use at this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of its affiliates, directors, officers, advisors or representatives will be liable (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising from or in connection with this presentation.

This presentation contains statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this presentation, except as required by law.

AGENDA



01 1H 2023: Strategic Growth

02 Harbour Therapeutics: Strong Execution on Pipeline

03 Nona Biosciences: Technology Drives Therapeutic Innovation

04 Business & Financial Review

05 Outlook

1H 2023: Strategic Growth

Dr. Jingsong Wang

Founder, Chairman of the Board and Chief Executive Officer



Strong Growth Through Innovation & Strategic Focus



Portfolio Advancement

- Focus on driving key clinical programs to major value inflection points
- Differentiated innovations fully leverage core technology platforms
- Continue to improve operation efficiency



Platform Upgrade

- **Harbour Mice[®]: Innovation for upgraded efficiency**
- **HCAb PLUS[™] : Versatile to new modalities**
- **Expanded applications in challenging field: ICE, ADC and GPCR...**



Business Enhancement

- Global partnership with MNCs
- Co-development with leading biotechs
- Regional collaboration to maximize program value
- Expansive BD effort in realizing the value of the technology platform

Business Highlights on Harbour Therapeutics

Multiple Major Milestone Achievements in Advancing Global Product Portfolio



Batoclimab (HBM9161) BLA submission



Progress in clinical stage assets

- **2** new clinical data readouts from Porustobart (HBM4003)
- **2** clinical program advancement milestones
 - HBM9378 completed subjects dosing of Phase I trial
 - HBM1020 initiated Phase I trial in the U.S.
- **4** new IND approval
 - HBM1020, HBM1007, HBM1022 & HBM9033




Progress on collaboration assets

- **1** clinical asset regionally out-licensed to accelerate the global development
- **4** new INDs from partners
 - AstraZeneca: HBM7022/AZD5863 in CN&US
 - Hualan Genetics: HBM7020, HBM7015
 - NK Celltech: NK-010



恩凯赛药
NK CELLTECH

Transformational Engine for New Growth Via Nona



Broaden the Business Models Through Global Collaborations



Business development

- **>30** on going collaboration projects
- **Global** key accounts



Technology services

- **20+** projects kick-off
- **ADC** discovery service officially launched
- **Well-established** discovery management system



Contributions to Increasing Revenue

- Near **USD 10M** external revenue


Sustainable Business Models to Drive Sustainable Value Creation

Business Highlights

- ✓ Projects advance to late-stage
- ✓ Multiple positive readouts
- ✓ Comprehensive I/O pipeline
- ✓ Integrate capability in ADC
- ✓ Emerging in mRNA + bsAb

Financial Highlights

- ✓ Revenue growth >40% in 1H of 2022&2023
- ✓ Sustained BD with MNCs and Biotechs
- ✓ Effective control on operation
- ✓ Achieve positive profit for the first time
- ✓ Sufficient cash reserves



▪ Global version in innovation

▪ Maximization of platform value

▪ Sustainable collaborations








Harbour Therapeutics: Strong Execution on Pipeline

Dr. Xiaolu Tao

Chief Development Officer



Highly Innovative and Differentiated Global Pipeline

Project	Target	Indication	Commercial Rights	Status						
				Discovery	Pre-Clinical	IND	Phase I	Phase II	Phase III	BLA
Batoclimab HBM9161	FcRn	Myasthenia Gravis	Greater China Rights Out-licensed ¹	BLA submission 						
Porustobart HBM4003	CTLA-4 ²	Solid Tumors ^a	Global	Monotherapy Ph 1b/2						
		Solid Tumors ^b		Combo with PD-1 Ph 1b/2						
		Solid Tumors ^c		Combo with PD-1/PD-1+Chemo Ph 1						
HBM7008	B7H4×4-1BB	Solid Tumors	Ex-U.S. ³	Ph 1 						
HBM9378	TSLP	Asthma	Global	Ph 1 						
HBM1020	B7H7/HLA2	Solid Tumors	Global	Ph 1						
HBM7022	CLDN18.2×CD3	Solid Tumors	Global Out-license	Ph 1/2 						
HBM1007	CD73	Solid Tumors	Global	US IND clearance in January 2023						
HBM1022	CCR8	Solid Tumors	Global	US IND clearance in February 2023						
HBM9033	MSLN ADC	Solid Tumors	Global	US IND clearance in August 2023						
HBM9027	PD-L1×CD40	Solid Tumors	Global							
HBM7004	B7H4×CD3	Solid Tumors	Global							
HBM1047	CD200R1	Solid Tumors	Global							
HBM9014	LIFR	Solid Tumors	Global							

Batoclimab (HBM9161)

Breakthrough Therapeutics for IgG Mediated Autoimmune Diseases

Significant Marketing Opportunity
in Autoimmune Disease

60~70


pathogenic IgG mediated
autoimmune diseases




Batoclimab (HBM9161)

First positive efficacy of FcRn inhibitors in Asian population in patients with Generalized Myasthenia Gravis

China's Fast-Growing Market Opportunity in Autoimmune Diseases




Global anti-FcRn therapies sales grow rapidly



Batoclimab (HBM9161) Provide Promising Value to Myasthenia Gravis Patients

DESIGN

132 adult gMG patients
 AChR/MuSK antibody positive and negative
 MGFA Class IIa to IVa
 MG-ADL score ≥ 5
 QMG score ≥ 11
2 weeks screening




All patients receive initial treatment cycle
 (Subcutaneous Injection once weekly for 6 weeks)

Individualized treatment cycles
 (≤ 2 cycles in 24 weeks)
 Time between cycles determined by duration of clinically meaningful improvement


RESULTS

Trial data showed batoclimab was safe and well tolerated, with statistically significant and clinically meaningful benefit :


- Demonstrated deep MG-ADL response in both treatment cycles
- Sustained efficacy with batoclimab was found in the second treatment cycle



Patients with sustained MG-ADL improvement




Porustobart (HBM4003) **Next-Gen Anti-CTLA-4 Antibody with Potential to be the Mainstream of IO Therapeutics**



Competitive Advantages

- 1 Deplete intra-tumoral Treg cells via enhanced ADCC strategy
- 2 Great safety profile resulted from the reduced systemic drug exposure
- 3 Huge potential for combination therapies



HCAb

Brianna M Lax., et al., Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. *PNAS*. 2023 Aug;120(31)

A total of **187** patients had been treated with Porustobart in clinical studies



Favorable Safety Profile



Promising Efficacy

- Objective responses in HCC, CRPC, melanoma and NEN treated with Porustobart monotherapy or combination therapy.
- Porustobart plus anti-PD-1 antibody showed improved response rate in mucosal and acral melanoma, HCC and NEN compared with currently available anti-CTLA-4 antibodies.


Porustobart (HBM4003)

Robust Clinical Benefit in Melanoma Patients

Robust efficacy observed for HBM4003 + Toripalimab in PD-1 naïve melanoma cohort

Best Overall Response by RECIST 1.1, N (%)

Pts with tumor assessments	15 (100%)
ORR (CR + PR)	5 (33.3%)
DCR (CR + PR +SD)	11 (73.3%)
Tumor reduction	9 (60.0%)



Robust efficacy observed for HBM4003 + Toripalimab in PD-1 naïve mucosal melanoma subgroup

Best Overall Response by RECIST 1.1, n (%)

Pts with tumor assessments	5 (100%)
ORR (CR + PR)	2 (40.0%)
DCR (CR + PR +SD)	4 (80.0%)
DOR	9m+, 12m+
Tumor reduction	4 (80.0%)

ORR in 2L PD-1 Naïve Chinese Mucosal Melanoma Patients

Treatment	Observed ORR
Pembrolizumab (KEYNOTE-151)	13.3%
Toripalimab (NCT03430297)	0%
Pucotenlimab (NCT04749485)	8.7%
Toripalimab + Axitinib	17.5%

Mucosal melanoma represents significant unmet medical needs in Asian population

☐ No 2nd Line treatment nor effective 1st Line treatment options




Porustobart (HBM4003)

Great Opportunities in High-grade Neuroendocrine Neoplasm (NEN)/NEC

HBM4003 + Toripalimab elicited significant efficacy improvement in high-grade NENs patients


Best Overall Response by RECIST 1.1, N (%)

Pts with tumor assessments	19 (100%)
ORR (CR + PR)	7 (36.8%)
DCR (CR + PR +SD)	11 (57.9%)
Tumor reduction	12 (70.6%)



HBM4003 + Toripalimab elicited the highest response rate in high-grade NENs patients

ORR of various treatments in high grade NENs / NEC




- Platinum-based chemotherapy was in the first line setting for advanced extra-pulmonary poorly differentiated NEC
- No established standard treatment in second line setting.
- Single agent or combination chemotherapies were commonly used with a median ORR of 18% and median OS of 7.64 months

Porustobart (HBM4003)


Clinical Benefit in Advanced HCC Patients

Robust efficacy observed for HBM4003 + Toripalimab in post-TKIs HCC patients

Best Overall Response, n(%)	RECIST 1.1	mRECIST
Pts with tumor assessments	15 (100%)	15 (100%)
CR	0 (0%)	0 (0%)
PR	7 (46.7%)	7 (46.7%)
ORR (CR + PR)	7 (46.7%)	7 (46.7%)
SD	4 (26.7%)	3 (20.0%)
DCR (CR + PR +SD)	11 (73.3%)	10 (66.7%)
Tumor reduction	10 (66.7%)	10 (66.7%)




HBM4003 + Toripalimab elicited high response rate in HCC patients



- Preliminary data of 4003.5 study (NCT05149027), Cohort 1: 2L HCC patients who failed previous anti-VEGFR TKI treatments were treated with HBM4003 0.45mg/kg + toripalimab 240mg
- 16 patients treated, of whom 15 patients had at least one post treatment tumor assessment
- Median follow up 3.4 months (range: 1~5 months)

Porustobart (HBM4003) Pivotal Trial Preparation



HBM1020 (B7H7/HHLA2)

An Alternative Immune Escape Mechanism Beyond PD-L1







Highlights

- ❑ T cell and NK cell activation activity and excellent in vivo efficacy in humanized tumor models
- ❑ Widely Expressed in Various Solid Tumors & Reciprocal to the Expression of PD-L1
- ❑ Huge potential to treat PD-L1 negative or anti-PD1/PD-L1 refractory cancer patients
- ❑ HBM1020 is the first and only mAb entering clinical development worldwide
- ❑ **Ph1 ongoing - multiple patients dosed in collaboration with top-tier US cancer centers**



Widely Expressed in Various Solid Tumors & Reciprocal to the Expression of PD-L1



B7H7 and PD-L1 expression in NSCLC
WO 2019204057A1

HBM9033 (MSLN)

Next-Gen Mesothelin ADC for Solid Tumors



Highlights


- ❑ Unique fully human antibody warhead with improved binding, internalization, blocking activity and less interference by sMSLN
- ❑ The 4th generation novel payload with tumor-specific cleavable linker and high serum stability
- ❑ Superior therapeutic window compared to other ADC technologies
- ❑ **IND clearance in August 2023, Phase I trial expected in 2H 2023**




Robust anti-tumor activities and better PK/PD profile observed in preclinical studies

Conjugation	Non-maleimide based S-bond formation
Linker	Tri-peptide cleavable linker (unnatural aa included)
Payload	Topoisomerase inhibitor with higher potency than Dxd, DAR 8

Better efficacy than DXd based ADC in mouse CDX model



Confirmed in-vivo stability of ADC shows minimal payload release in monkey



HBM7022/AZD5863

Novel 2+1 Format from HBICE® Platform Validated by MNC




Highlights

- ❑ 2+1 format with better activity and potential larger therapeutic window
- ❑ Low CD3 and high CLDN18.2 affinity reduce systemic exposure and increase distribution to tumor
- ❑ Silent Fc extends half-life, avoids Fc crosslinking and ADCC
- ❑ **Global Phase I/II study initiated in 2023.7**

Anti-CD3:

- Optimized anti-CD3 for less CRS
- Monkey cross-reactivity



Fc domain:

- Eliminated FcγR reactivity
- Knob into hole


Tandem anti-CLDN18.2 VH:

- High avidity binding
- Heavy chain only
- Fully human

HARBOUR
BIOMED



AstraZeneca



Advanced to clinical stage in 12-months

NCT06005493

Location	17 sites in US, Mainland and Taiwan, Japan, Korea, Netherlands
Estimated Enrollment	200 participants
Intervention Model Description	Individual modules of AZD5863 dosed as monotherapy: <ul style="list-style-type: none"> ▪ Module 1: AZD5863 intravenous administration ▪ Module 2: AZD5863 subcutaneous administration Modules 1 and 2 each consist of two parts: Part A, Dose Escalation and Part B, Dose Expansion.
Conditions	Gastric Cancer; Gastro-esophageal Junction Cancer; Pancreatic Ductal Adenocarcinoma; Esophageal Adenocarcinoma


HBM7008 (B7H4x4-1BB)

First-in-Class Bispecific Antibody from HBICE® Platform



Highlights


- Fully human **bispecific antibody** from the HBICE® platform
- Novel immune escape pathway - **First-in-class** target (B7H4x4-1BB)
- **Excellent safety profile**, potential to avoid 4-1BB liver toxicity with the benefit of its innovative mechanisms and bispecific design



HARBOUR
BIOMED



cullinan
ONCOLOGY



Collaboration accelerates global clinical development

NCT05306444

Location	7 sites in US and Australia
Estimated Enrollment	108 participants
Intervention Model Description	Part A, Dose Escalation Part B, Dose Expansion
Conditions	Advanced solid tumors

Nona Biosciences: Technology Drives Therapeutic Innovation

Dr. Yun He

Chief Technology Officer





Nona Biosciences Empowers Global Therapeutic Innovation





Nona:
Roman Goddess
Who Enables Others
to Succeed

Mission


Leveraging industrial leading technology platforms, Nona Biosciences is committed to provide integrated discovery solution for biotech and pharmaceutical companies from **Idea to IND (I to I)**.

Technologies

Harbour Mice®



Expertise



Partners

moderna®

MYTHIC
THERAPEUTICS

DualityBio
映恩生物

Dragonfly

Business


Innovation

Licensing

Services



Three Pillars to Drive Business Achievement in 2023H1




Consistently Advances **Technology Innovation:**

- ✓ ADC Discovery Platform
- ✓ mRNA-encoded HBICE®
- ✓ Exploration in CAR-T, protein degradation, etc.




Expand Harbour Mice® Fully Human Antibody Platforms to Emerging Fields






Nona Biosciences Consistently Advances Technology Innovation

Protein Engineering




Combine human antibody platforms and **protein engineering** to generate multifunctional molecules

Conjugation Technology



Novel **conjugation technology** for bringing new modalities against solid tumors

Delivery Technology



mRNA technology to bring solutions for difficult targets or new therapy

Artificial Intelligence



Artificial Intelligence for accelerating antibody discovery and optimization




Extend Antibody Discovery Platform to Integrated ADC Discovery Platform



H2L2




HCAb





HBICE



Antibody-lead finding and optimization based on Nona's Ab discovery platform



Deep understanding of ADC molecules




PK studies, in vivo stability assessment



Comprehensive bioconjugation technology

- ✓ Rich payload-linker library
- ✓ Proprietary DAR2 site-specific conjugation




Full range of in vitro bioactivity studies for both mAb and ADC

Explore Frontiers in ADC Field

Collaborate with global ADC experts to build ADC ecosystem

Unveil the advantages of bispecific / biparatopic ADC


Application of HCAb in XDC for Diagnosis & Therapy



Radiolabeled anti-MSLN HCAb can quickly penetrate into tumors






bsAb showed stronger internalization



H2L2-ADC to MSLN


- ✓ fully human antibody with unique binding epitope
- ✓ Tumor specific cleavable linker with improved stability
- ✓ Superior in vivo potency and promising safety profile

US IND clearance in Aug 2023





Comprehensive Bispecific Antibody Discovery Workflow to Reinforce Industry-leading HBICE® Platform (HCAb Based Immune Cell Engagers)



HBICE® Platform Has Been Endorsed by Global Partners



HBM7022 (CLDN18.2×CD3)

Unique 2+1 format with better activity and potential larger therapeutic window.




HBM7008 (B7H4×4-1BB)

First-in-class B7H4 ×4-1BB with excellent anti-tumor efficacy and safety profile.







Upgrade Next-Gen HBICE[®] to Strengthen Our Leading Position in Bispecific Antibody Discovery



- ✓ Unique multivalent formats.
- ✓ Optimized CD3 arm to balance cytotoxicity and cytokine release.
- ✓ Crosslinking-dependent 4-1BB HCAs without liver toxicity.



- ✓ Leverage **CD3 HCAb** to build **tri-specific** engagers, incorporating both 1st signal (CD3) and 2nd signal (4-1BB/CD28) into single modality to fully unleash T-cell activity.




- ✓ **mRNA-encoded** HCAb-based bi-/tri-specific engagers for in vivo delivery.
- ✓ Bring more efficient and cost-effective solution for new therapeutics

Combine mRNA & HBICE® Technologies to Create Next-Gen Therapeutics


mRNA-encoded TAAxCD3 engager can elicit excellent therapeutic potential with higher response rate, anti-tumor activity and longer treatment duration.

- ✓ Combination of mRNA technology and HBICE® platform
- ✓ Circumvent limitations of CMC challenges and short serum half-life for T cell engager
- ✓ Better stability and efficiency to accelerate the clinical development




HBICE-4-mRNA is mRNA-encoded TAAxCD3 engager in single chain format, encapsulated by LNP

Cytotoxicity on Tumor Cells



PBMC Humanized Tumor Model



HBICE-4 is TAAxCD3 engager in single-chain format, purified protein.
Luc-mRNA is mRNA-encoded Luciferase serving as negative control.

Nona Biosciences Leverages Industry-leading Technology Platforms to Empower Global Therapeutic Innovation

Clinically Validated Platforms

- **50+** industry and academic partners
- **17+** projects entered clinical stage



H2L2



HCAb



HBICE

Continuous Technology Innovation

- HCAb PLUS
- Bispecific Ab
- ADC / XDC
- Ab+ mRNA
- Ab+ AI

Experienced Scientific Team

- **3** innovation centers
- **70+** experienced research scientists
- Track record of advancing **10+** FIC/BIC candidates into development

Rapid Business Growth

- **20+** new partners
- **30+** collaboration projects ongoing
- **~ \$ 10 M** revenue acknowledged




Business & Financial Review

Mr. Weihao Xu

Chief Financial Officer and Chief Business Officer



Significant Global Collaborations Unleashed Powerful Technology



- Deliver antibody therapies quickly
- Bring treatment to address emerging need

- HCAb PLUS™: versatile modalities
- Nona Bioscience: partnered in broad application

- Integrated ADC discovery platform application

Y 2021: Platform with high efficiency

Y 2022: Advancing core technologies for next-gen therapeutics

Y 2023: Sustainable business development

■ Collaboration with Cullinan
■ Co-development on HBM7008 Drives Speed and Delivers both Short/Long Term Values

Principal Terms

HARBOUR
BIOMED

cullinan
ONCOLOGY



Upfront Payment

- \$25 million



Milestone Payment

- Up to \$600 million



Royalties

- Up to high teens



Collaboration and Co-development

- US development and commercial rights
- Access to EU & Australia Patient population



Validation of the assets and company's platform




Integrate the internal and external resources



Expand cooperation network with global strategic perspective



Nona Biosciences Consistently Builds Innovation Ecosystem



A dashed blue rounded rectangle contains the following logos and text:

- PharmaEssentia™
Better Science . Better Lives.
- DualityBio moderna
映恩生物
- Dragonfly UNIVERSITY OF WASHINGTON
VERITAS
- ModeX™
THERAPEUTICS
an OPKO Health Company
- MYTHIC
THERAPEUTICS

The Harvard Medical School logo (a shield with a lion and the word 'VERITAS') is followed by a large 'X' symbol and the text 'HBM Alpha'.

The logo for Sobour Biopharma, featuring a stylized globe with a red cross and the Chinese characters '崧铂医药' above the English name 'SOBOUR BIOPHARMA'.

The logos for Harbour Biomed and Nona Biosciences are displayed at the bottom left of the slide.

Value Creation Through Business Development

Cash Received
2022 - 1H2023

> \$ 95 M

Collaborations achieved
from 2022 to 2023



Potential Milestones

~ \$ 3 B

Potential milestones generated
from collaborations since 2023



Royalties


Tiered royalties on
potential net sales



2023 Interim Results Positive Profit


Projected Revenue

Total revenue of the Group increased significantly from US\$27.6 million for the six months ended 30 June 2022 to US\$41.0 million for the six months ended 30 June 2023, primarily due to the increase in our revenue from recognizing molecule license fee.



Profit for the Period

Profit for the period was recorded US\$2.9 million for the six months ended 30 June 2023, compared to a loss for the period of approximately US\$73.1 million for the six months ended 30 June 2022.






Collaborations Improve the Efficiency of R&D

Research and development costs

Research and development costs decreased significantly from US\$83.6 million for the six months ended 30 June 2022 to US\$28.4 million for the six months ended 30 June 2023.

This decrease was primarily attributable to :

- ❑ Decreased investments in clinical trials after multiple out-licensing transactions
- ❑ Decrease of our R&D staffs and share-based payment expenses




Effective Control on Operation

Administrative expenses

Administrative expenses decreased by US\$6.8 million to US\$8.6 million for the six months ended 30 June 2023

This decrease was primarily attributable to :

- ❑ Decrease in employee cost from US\$10.8 million for the six months ended 30 June 2022 to US\$5.5 million for the six months ended 30 June 2023, caused by the decrease of salary and welfare in relation to our administration headcount.





Healthy Cash Position to Drive Value Creation


Summary of Consolidated Statements of Financial Position

USD Mil	30 June	31 December
	2023	2022
Non-current assets	20.5	23.1
Current assets	203.0	209.0
Include:		
Cash and bank balances	<u>179.3</u>	<u>171.7</u>
Current liabilities	64.6	75.0
Net current assets	138.4	134.0
Non-current liabilities	58.5	64.6
Net assets	100.4	92.5

Cash and bank balances

Cash and bank balances increased from US\$171.7 million to US\$179.3 million.

USD Mil



Outlook

Dr. Jingsong Wang

Founder, Chairman of the Board and Chief Executive Officer



Harbour BioMed Bridging to New Era

Develop drugs and drug candidates with unique platform and excellent talent, ultimately bring the idea to fruition



- Harbour Therapeutic


Multiple catalysts expected in next six months

- HBM4003 pivotal trial initiation
- HBM1020 preliminary safety and efficacy data readout
- HBM7008 phase I data readout in early 2024
- HBM9033 Phase 1 initiation

- Nona biosciences

Provides fully integrated solutions from I to ITM

- Continuous innovation on platform
- Expanding collaborations
- Integrated discovery solution for ADC, bispecific antibody, mRNA encoding.....



Q & A



THANK YOU

